Loading...
Loading...
Stifel Nicolaus reiterated its Buy rating on Team Health Holdings
TMH and raised its price target from $29 to $30.
Stifel Nicolaus commented, "Team stands to benefit from healthcare reform in two ways. Raising Medicaid payments to physicians for primary care services to the level of Medicare in 2013-14 will boost revenues for Team's emergency department services, and expansion of insurance coverage to the uninsured scheduled to begin in 2014 will reduce the number of low- or no-pay uninsured patients treated in Team's emergency departments. We believe that Team's continued strong fundamental performance illustrates that health reform is a not a prerequisite for share price appreciation. Our earnings model, target price, and Buy rating all assume no health reform benefit."
Team Health Holdings closed at $26.61 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in